Physician profile
Arden Acob
NPI 1982614871
$15,799.66
in general payments reported to CMS, 2019-2025
51 companies · $2,344 in 2025
The $2,344 reported for 2025 was more than what 75% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,741 · 2020: $1,816 · 2021: $1,914 · 2022: $2,192 · 2023: $2,267 · 2024: $2,526 · 2025: $2,344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,029 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,029.05 |
| Education | $108.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,701.80 | 2019-2025 | Rystiggo, Briviact, Nayzilam |
| Livanova USA, INC. | $1,636.45 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Abbvie INC. | $1,526.83 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Lilly USA, LLC | $980.11 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Amgen INC. | $792.62 | 2019-2023 | Aimovig |
| Otsuka America Pharmaceutical, INC. | $576.76 | 2019-2025 | Rexulti, Abilify Maintena |
| Biohaven Pharmaceuticals, INC. | $502.02 | 2020-2021 | |
| Neurelis, INC. | $487.47 | 2023-2025 | Valtoco |
| Pfizer INC. | $483.01 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $474.40 | 2019-2022 | |
| Medtronic, INC. | $446.10 | 2022-2025 | Minimed 780g, Minimed 770g |
| Teva Pharmaceuticals USA, INC. | $430.24 | 2020-2025 | Austedo Xr, Austedo Xr |
| Impel Pharmaceuticals INC. | $381.68 | 2023 | Trudhesa |
| Neurocrine Biosciences, INC. | $369.55 | 2021-2025 | Ingrezza, Ongentys |
| Merck Sharp & Dohme LLC | $352.52 | 2019-2023 | Verquvo, Belsomra |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arden Acob listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.